Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

J. Bone Miner Res 2014; 29: 935–943. DOI: 10.1002/jbmr.2092

Conclusions: These findings support further investigation of blosozumab as a potential anabolic therapy for osteoporosis.